NCT06004986Active, not recruitingPhase 4
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
DUPI REDUCE Trial (DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema): a Multicenter, Low-intervention, Non-inferiority Randomized Controlled Trial, Embedded in the TREAT NL Registry
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 216 (estimated)
- First submitted
- 15 Aug 2023
- Start date
- 14 Aug 2023
- Primary completion date
- 5 Nov 2026
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06004986
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 216
- From 14 Aug 2023 to the primary completion date, 5 Nov 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The subjects uses or initiates another systemic immunomodulating therapy for AE or another diagnosis.
Who the study is looking for
- The subject is an adult,
- Has a diagnosis of AE,
- Receives dupilumab 300 mg q2w for the treatment of AE,
- Has controlled disease according to the Treat-to-Target criteria,
- Agrees to the possibility that the dosage of dupilumab will be lowered,
- Has voluntarily signed and dated an informed consent prior to any study related procedure.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam University Medical Centers Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
| Erasmus Medical Center Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.